Education
About Us
Working with TipRanks
Follow Us
Mustang Bio (MBIO)
:MBIO
Mb-106
Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-Cell Non-Hodgkin's Lymphoma, B-Cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory, Chronic Lymphoid Leukemia In Relapse
Phase I/II
Terminated
Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL
Apr 14, 2022
―
Cyclophosphamide, Fludarabine, Mb-102
Blastic Plasmacytoid Dendritic Cell Neoplasm (Bpdcn)
Phase I/II
Terminated
Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.
Sep 25, 2019
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Mustang Bio (MBIO) have in its pipeline
MBIO is currently developing the following drugs: Mb-106, Cyclophosphamide, Fludarabine, Mb-102. These drug candidates are in various stages of clinical development as the company works toward FDA approval.